Pitavastatin, a cholesterol lowering drug, slashes chemotherapy resistance in breast cancer by obstructing a specific protein ...
Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...
Tumor cells can trigger angiogenesis by a process involving physical contact with neighboring endothelial cells, scientists report in this month's issue of Cancer Cell. This is the first time, ...
News-Medical.Net on MSN
Pitavastatin shows pomise in overcoming chemotherapy resistance in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...
Discover how Pitavastatin, a cholesterol-lowering drug, shows promise as a treatment for triple-negative breast cancer.
A Korea University research team has discovered that pitavastatin, a widely used lipid-lowering drug, can directly inhibit ...
An artificial saliva in the form of a mouthwash, produced with the CANECPI-5 protein extracted from sugarcane and modified in a laboratory, can aid in ...
We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience,” said Thomas Schuetz, MD, PhD, CEO ...
Compass Therapeutics ( ($CMPX) ) has issued an update. On January 6, 2026, Compass Therapeutics reported an estimated, unaudited cash and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback